INTRODUCTION
Prostate cancer (PCa) is the most common solid organ malignancy in men in many western countries including the United States and is the fifth most common in Korean males. [1] [2] [3] PCa shows an extremely heterogeneous clinical course, ranging from indolent and organ-confined to aggressive, metastatic lethal disease, leading to the overtreatment of men with relatively indolent disease and the undertreatment of those with aggressive tumors. 4, 5 Consequently, there is a great need to accurately assess the tumor characteristics of PCa so that appropriate treatment options can be considered.
Currently, pathological analyses (including clinical stage and tumor grade in biopsy as measured by the Gleason score) and serum prostate-specific antigen (PSA) levels are key determinants for risk assessment and therapeutic decision-making. 6 However, none of the histological criteria or biomarkers reported to date show sufficient sensitivity or specificity for detecting, monitoring, and determining the prognosis of PCa. D' Amico et al. 7 were the first to combine the use of preoperative PSA levels, clinical stage, and biopsy Gleason Patients who received neo-adjuvant treatment (n = 8) or adjuvant radiotherapy (n = 6, four patients also received neo-adjuvant treatment) were excluded. As a result, 203 subjects satisfied the final inclusion criteria.
RARP was carried out using our standardized extraperitoneal technique by a single surgeon (YDC). 15 The study was carried out in agreement with applicable laws and regulations, good clinical practices, and ethical principles as described in the Declaration of Helsinki. The Institutional Review Board of the hospital approved the present study protocol (Approval number: 4-2014-0619). Favorable pathology was defined as a Gleason score ≤6 and organ-confined cancer as detected by surgical pathology. BCR was defined as two sequential PSA values ≥0.2 ng ml −1 after prostatectomy. Continuous variables are shown as the median and IQR. Differences in variables with a continuous distribution across dichotomous categories were assessed using the Mann-Whitney U-test. The Fisher exact test was used to evaluate the association between categorical variables. PSAD was categorized into approximate quartiles within the nested subcohort, with the highest quartile assigned as the reference group. Survival analyses were conducted according to the Kaplan-Meier method, and survival characteristics were compared using the log-rank test. Univariate and multivariate Cox regression model was used to identify the independent prognostic factors for BCR following RARP. Variables of P < 0.1 on univariate analysis included in the multivariate analysis. Statistical significance was considered at P < 0.05, and all reported P values are two-sided. Analysis was performed using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). 
RESULTS

Baseline characteristics
Clinical variables associated with favorable pathology in patients with IRPCa
Preoperative PSAD and CAPRA score were significantly associated with favorable pathology after RARP (P = 0.017, P = 0.013, respectively). However, there were no significant differences among the favorable and unfavorable pathology groups with respect to other preoperative variables, including age, BMI, preoperative PSA, and clinical stage and grade ( Table 2) .
When PSAD was categorized into quartiles, the lower quartile PSAD group was associated with favorable pathology compared with the highest quartile PSAD group after adjusting for PSA, clinical stage, and biopsy Gleason score (odds ratio, 5.42; 95% confidence interval [CI], 1.01-28.97; P = 0.048) ( Table 3) .
Prediction of BCR after radical prostatectomy in patients with IRPCa
During a median 37.8 (interquartile range 24.6-60.2) months of follow-up, 66 patients (32.5% of the IRPCa cohort) experienced BCR and the majority of BCR (95.5%) were occurred in unfavorable pathology group. One-and 3-year BCR-free survival rates were 94.6% and 91.8% for patients with favorable pathology, whereas 78.9% and 63.9% for patients with unfavorable pathology.
Kaplan-Meier analysis exhibits significantly different BCR-free survival by PSAD quartiles (log-rank P = 0.003) (Figure 1 ). Table 4 shows results from univariate and multivariate Cox proportion hazard analysis for prediction of BCR after RARP. In univariate analyses, lower preoperative PSA, PSAD, CAPRA score, LVI and positive surgical margins were associated with BCR after RARP. When multivariate analysis with PSAD, PSAD (hazard ratio [HR], 4.641; 95% 
DISCUSSION
The current study investigated the preoperative variables of favorable pathology and the risk of BCR in patients with IRPCa. Our study showed that approximately 20% of patients with IRPCa had a favorable pathology as detected by final pathology. Preoperative PSAD was not only associated with favorable pathology, but also an independent predictor of BCR in patients with IRPCa after prostatectomy. PSAD might be an additional tool for stratifying men with IRPCa and identifying some patients in whom AS would be appropriate in this setting. PCa shows an extremely heterogeneous clinical course, ranging from indolent and organ-confined to aggressive, metastatic lethal disease. [16] [17] [18] Moreover, we acknowledge that patients in each risk group have significant clinical heterogeneity, particularly IRPCa. 8, 9 The original research concerning within-group heterogeneity by Reese et al. 9 revealed heterogeneous pathologic and biochemical outcomes among men within a single NCCN risk group. In their PSAD was initially introduced to improve the sensitivity and specificity of PSA testing for PCa screening. 24 However, some groups have also examined the role of PSAD in predicting advanced pathology after radical prostatectomy or BCR after local treatment. 25, 26 PSAD has been adopted as criteria for AS in men with low-risk PCa. The NCCN and PRIAS AS protocols include PSAD as an inclusion criterion. Furthermore, a recent study showed that PSAD was associated with an upgraded Gleason score of the prostatectomy specimen. 27, 28 While it is well-known that PSAD is a useful tool for selecting candidates for AS and prediction of BCR after definitive treatment in low-risk disease, the prognostic implications of PSAD in IRPCa have not yet been sufficiently elucidated. Our results suggest the potential utility of PSAD in predicting the favorable pathology and the risk of recurrence after surgery in IRPCa.
Recently, several investigators have reported the appropriateness of AS in select men with IRPCa, demonstrating favorable outcomes. 13, 14 The UCSF group reported that selected men with intermediate-risk features be appropriate candidates for AS, and are not necessarily more likely to progress. 29 Better risk assessment through emerging biomarkers and better integration of clinical predictors could discriminate significant from indolent tumors in men with IRPCa. PSAD might be an additional tool for appropriate selection for AS in IRPCa. Further prospective design is needed to confirm the clinical application of PSAD for AS and consequent oncologic safety assessment in intermediate-risk disease.
Our study has both strengths and limitations. It had a retrospective design, which means that there may have been some sampling bias. However, the RARP data originated at a single institution and a single surgeon, minimizing performance variability within groups and decreasing performance bias. In addition, current study cohort consisted entirely of men treated with RARP. Thus, the prognostic implications of PSAD in IRPCa patients treated with brachytherapy, external beam radiotherapy, hormone suppression, and combinations of these modalities should be validated in future studies.
CONCLUSIONS
PSAD is associated with favorable pathology and is an independent predictor of BCR in patients with IRPCa after surgery. PSAD might be an additional tool for sub-stratifying patients with IRPCa into different prognostic groups and identifying some patients in whom AS would be appropriate in this setting.
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